GB0613925D0 - Improvements relating to nanodispersions - Google Patents

Improvements relating to nanodispersions

Info

Publication number
GB0613925D0
GB0613925D0 GBGB0613925.7A GB0613925A GB0613925D0 GB 0613925 D0 GB0613925 D0 GB 0613925D0 GB 0613925 A GB0613925 A GB 0613925A GB 0613925 D0 GB0613925 D0 GB 0613925D0
Authority
GB
United Kingdom
Prior art keywords
nanodispersions
improvements relating
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0613925.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Original Assignee
Unilever PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC filed Critical Unilever PLC
Priority to GBGB0613925.7A priority Critical patent/GB0613925D0/en
Publication of GB0613925D0 publication Critical patent/GB0613925D0/en
Priority to US12/309,306 priority patent/US20090175953A1/en
Priority to EP07786932.9A priority patent/EP2040680B1/en
Priority to CA002656233A priority patent/CA2656233A1/en
Priority to CN2012101088434A priority patent/CN102631874A/zh
Priority to EP07786933.7A priority patent/EP2040681B1/en
Priority to MX2009000307A priority patent/MX2009000307A/es
Priority to PCT/EP2007/056561 priority patent/WO2008006713A2/en
Priority to ZA200900029A priority patent/ZA200900029B/xx
Priority to PCT/EP2007/056560 priority patent/WO2008006712A2/en
Priority to BRPI0714179-3A priority patent/BRPI0714179A2/pt
Priority to ZA200900028A priority patent/ZA200900028B/xx
Priority to EP07765734A priority patent/EP2040678A2/en
Priority to JP2009518832A priority patent/JP2009542761A/ja
Priority to ZA200900027A priority patent/ZA200900027B/xx
Priority to EP07786931A priority patent/EP2040679A2/en
Priority to CA002656217A priority patent/CA2656217A1/en
Priority to JP2009518831A priority patent/JP2009542760A/ja
Priority to ZA200900030A priority patent/ZA200900030B/xx
Priority to ES07765733T priority patent/ES2741124T3/es
Priority to ZA200900031A priority patent/ZA200900031B/xx
Priority to CNA2007800262750A priority patent/CN101489533A/zh
Priority to US12/309,294 priority patent/US8821932B2/en
Priority to US12/309,295 priority patent/US20100015233A1/en
Priority to CN201010193750A priority patent/CN101849911A/zh
Priority to CNA2007800263575A priority patent/CN101489534A/zh
Priority to CNA2007800262657A priority patent/CN101489532A/zh
Priority to MX2009000309A priority patent/MX2009000309A/es
Priority to CA002656223A priority patent/CA2656223A1/en
Priority to CA2656229A priority patent/CA2656229C/en
Priority to JP2009518833A priority patent/JP2009542762A/ja
Priority to AU2007271827A priority patent/AU2007271827B2/en
Priority to US12/309,292 priority patent/US9060937B2/en
Priority to JP2009518835A priority patent/JP2009542764A/ja
Priority to JP2009518834A priority patent/JP2009542763A/ja
Priority to EP11005052A priority patent/EP2386292A1/en
Priority to PCT/EP2007/056562 priority patent/WO2008006714A2/en
Priority to PCT/EP2007/056563 priority patent/WO2008006715A2/en
Priority to EP20100175541 priority patent/EP2269581A1/en
Priority to AU2007271831A priority patent/AU2007271831B2/en
Priority to EP11005053A priority patent/EP2387992A1/en
Priority to US12/309,293 priority patent/US20090239749A1/en
Priority to ES07786932T priority patent/ES2752460T3/es
Priority to PCT/EP2007/056564 priority patent/WO2008006716A2/en
Priority to AP2008004713A priority patent/AP2008004713A0/xx
Priority to CA002659666A priority patent/CA2659666A1/en
Priority to BRPI0714230-7A priority patent/BRPI0714230A2/pt
Priority to CNA2007800263679A priority patent/CN101489535A/zh
Priority to CN2012101088167A priority patent/CN102671585A/zh
Priority to BRPI0722376-5A priority patent/BRPI0722376A2/pt
Priority to AU2007271829A priority patent/AU2007271829B2/en
Priority to AU2007271828A priority patent/AU2007271828B2/en
Priority to AU2007271830A priority patent/AU2007271830B2/en
Priority to CNA2007800262267A priority patent/CN101489531A/zh
Priority to BRPI0714177-7A priority patent/BRPI0714177A2/pt
Priority to EP07765733.6A priority patent/EP2040677B1/en
Priority to BRPI0714176-9A priority patent/BRPI0714176A2/pt
Priority to TW096125298A priority patent/TW200812694A/zh
Priority to CL2007002031A priority patent/CL2007002031A1/es
Priority to CL2007002030A priority patent/CL2007002030A1/es
Priority to CL2007002032A priority patent/CL2007002032A1/es
Priority to EP07766448A priority patent/EP2046295A1/en
Priority to ZA200900345A priority patent/ZA200900345B/xx
Priority to JP2009518979A priority patent/JP2009542794A/ja
Priority to AU2007274041A priority patent/AU2007274041A1/en
Priority to EP07766450A priority patent/EP2046297A2/en
Priority to CNA2007800338942A priority patent/CN101516342A/zh
Priority to CA002657548A priority patent/CA2657548A1/en
Priority to CA002657586A priority patent/CA2657586A1/en
Priority to AU2007274039A priority patent/AU2007274039A1/en
Priority to CNA2007800338285A priority patent/CN101516340A/zh
Priority to US12/309,343 priority patent/US20100008995A1/en
Priority to BRPI0714351-6A priority patent/BRPI0714351A2/pt
Priority to ARP070103116A priority patent/AR061990A1/es
Priority to US12/309,341 priority patent/US7691873B2/en
Priority to JP2009518978A priority patent/JP2009542793A/ja
Priority to PCT/GB2007/050407 priority patent/WO2008007150A1/en
Priority to ZA200900347A priority patent/ZA200900347B/xx
Priority to ARP070103117A priority patent/AR061991A1/es
Priority to CA002657582A priority patent/CA2657582A1/en
Priority to BRPI0714353-2A priority patent/BRPI0714353A2/pt
Priority to BRPI0714352-4A priority patent/BRPI0714352A2/pt
Priority to CNA2007800338444A priority patent/CN101516341A/zh
Priority to US12/309,344 priority patent/US8945626B2/en
Priority to JP2009518980A priority patent/JP2009542795A/ja
Priority to ARP070103118A priority patent/AR061992A1/es
Priority to EP07766449A priority patent/EP2046296A2/en
Priority to PCT/GB2007/050409 priority patent/WO2008007152A2/en
Priority to PCT/GB2007/050408 priority patent/WO2008007151A2/en
Priority to AU2007274040A priority patent/AU2007274040A1/en
Priority to IL195911A priority patent/IL195911A0/en
Priority to IL195933A priority patent/IL195933A/en
Priority to AU2010201900A priority patent/AU2010201900A1/en
Priority to CL2010000516A priority patent/CL2010000516A1/es
Priority to JP2010131047A priority patent/JP2010202665A/ja
Priority to ARP100102205A priority patent/AR077195A2/es
Priority to US13/365,830 priority patent/US20120135058A1/en
Priority to US13/365,826 priority patent/US20120134940A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
GBGB0613925.7A 2006-07-13 2006-07-13 Improvements relating to nanodispersions Ceased GB0613925D0 (en)

Priority Applications (98)

Application Number Priority Date Filing Date Title
GBGB0613925.7A GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions
US12/309,306 US20090175953A1 (en) 2006-07-13 2007-06-29 Nanodispersions
EP07786932.9A EP2040680B1 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
CA002656233A CA2656233A1 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
CN2012101088434A CN102631874A (zh) 2006-07-13 2007-06-29 纳米分散体的相关改进
EP07786933.7A EP2040681B1 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
MX2009000307A MX2009000307A (es) 2006-07-13 2007-06-29 Mejoras que se refieren a nanodispersiones.
PCT/EP2007/056561 WO2008006713A2 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions
ZA200900029A ZA200900029B (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
PCT/EP2007/056560 WO2008006712A2 (en) 2006-07-13 2007-06-29 Preparation of nanodispersions
BRPI0714179-3A BRPI0714179A2 (pt) 2006-07-13 2007-06-29 melhoramentos relacionados a composiÇÕes farmacÊuticas
ZA200900028A ZA200900028B (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
EP07765734A EP2040678A2 (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
JP2009518832A JP2009542761A (ja) 2006-07-13 2007-06-29 抗寄生虫組成物に関連する改良
ZA200900027A ZA200900027B (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions
EP07786931A EP2040679A2 (en) 2006-07-13 2007-06-29 Preparation of nanodispersions
CA002656217A CA2656217A1 (en) 2006-07-13 2007-06-29 Improvements relating to nanodispersions
JP2009518831A JP2009542760A (ja) 2006-07-13 2007-06-29 ナノ分散体に関する改良
ZA200900030A ZA200900030B (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
ES07765733T ES2741124T3 (es) 2006-07-13 2007-06-29 Mejoras con respecto a composiciones antiparasitarias
ZA200900031A ZA200900031B (en) 2006-07-13 2007-06-29 Improvements relating to nanodispersions
CNA2007800262750A CN101489533A (zh) 2006-07-13 2007-06-29 生物希伤剂组合物的相关改进
US12/309,294 US8821932B2 (en) 2006-07-13 2007-06-29 Pharmaceutical compositions
US12/309,295 US20100015233A1 (en) 2006-07-13 2007-06-29 anti-parasitic compositions
CN201010193750A CN101849911A (zh) 2006-07-13 2007-06-29 生物杀伤剂组合物的相关改进
CNA2007800263575A CN101489534A (zh) 2006-07-13 2007-06-29 抗寄生虫组合物的相关改进
CNA2007800262657A CN101489532A (zh) 2006-07-13 2007-06-29 与药物组合物相关的改进
MX2009000309A MX2009000309A (es) 2006-07-13 2007-06-29 Mejoras que se refieren a composiciones biocidas.
CA002656223A CA2656223A1 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions
CA2656229A CA2656229C (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
JP2009518833A JP2009542762A (ja) 2006-07-13 2007-06-29 殺生物性組成物に関連する改良
AU2007271827A AU2007271827B2 (en) 2006-07-13 2007-06-29 Improvements relating to nanodispersions
US12/309,292 US9060937B2 (en) 2006-07-13 2007-06-29 Pharmaceutical compositions
JP2009518835A JP2009542764A (ja) 2006-07-13 2007-06-29 医薬組成物に関連する改良
JP2009518834A JP2009542763A (ja) 2006-07-13 2007-06-29 製薬組成物に関連する改良
EP11005052A EP2386292A1 (en) 2006-07-13 2007-06-29 Improvements relating to nanodispersions
PCT/EP2007/056562 WO2008006714A2 (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
PCT/EP2007/056563 WO2008006715A2 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
EP20100175541 EP2269581A1 (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
AU2007271831A AU2007271831B2 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
EP11005053A EP2387992A1 (en) 2006-07-13 2007-06-29 Improvements relating to nanodispersions
US12/309,293 US20090239749A1 (en) 2006-07-13 2007-06-29 Biocidal compositions
ES07786932T ES2752460T3 (es) 2006-07-13 2007-06-29 Mejoras relacionadas con composiciones farmacéuticas
PCT/EP2007/056564 WO2008006716A2 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
AP2008004713A AP2008004713A0 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasetic compositions
CA002659666A CA2659666A1 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
BRPI0714230-7A BRPI0714230A2 (pt) 2006-07-13 2007-06-29 melhoramentos relacionados a composiÇÕes farmacÊuticas
CNA2007800263679A CN101489535A (zh) 2006-07-13 2007-06-29 纳米分散体的相关改进
CN2012101088167A CN102671585A (zh) 2006-07-13 2007-06-29 纳米分散体的相关改进
BRPI0722376-5A BRPI0722376A2 (pt) 2006-07-13 2007-06-29 composição fungicida livre de solventes, dispersão aquosa de um fungicida de estrobilurina, processo para preparar uma composição, processo para o tratamento de um substrato, processo para a entrega de um fungicida de estrobilurina, e, uso da composição
AU2007271829A AU2007271829B2 (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions
AU2007271828A AU2007271828B2 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions
AU2007271830A AU2007271830B2 (en) 2006-07-13 2007-06-29 Improvements relating to pharmaceutical compositions
CNA2007800262267A CN101489531A (zh) 2006-07-13 2007-06-29 与药物组合物相关的改进
BRPI0714177-7A BRPI0714177A2 (pt) 2006-07-13 2007-06-29 processo de preparo de composição biocida, composição biocida livre de solventes, dispersão aquosa, processo para o tratamento de um substrato, processo para a distribuição de um biocida e uso da composição
EP07765733.6A EP2040677B1 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions
BRPI0714176-9A BRPI0714176A2 (pt) 2006-07-13 2007-06-29 aperfeiÇoamentos relacionados À nanodispresço
TW096125298A TW200812694A (en) 2006-07-13 2007-07-11 Improvements relating to nanodispersions
CL2007002031A CL2007002031A1 (es) 2006-07-13 2007-07-12 Composicion farmaceutica que comprende una droga antiparasitaria insoluble en agua y un portador soluble en agua, en donde la droga se encuentra en la forma nano-dispersa; dispersion acuosa que la comprende; proceso para prepararla, util para el tratamiento o profilaxis de la malaria.
CL2007002030A CL2007002030A1 (es) 2006-07-13 2007-07-12 Composicion y proceso de preparacion de un biocida libre de solvente que comprende al menos un biocida insoluble en agua y un material portador soluble en agua en forma nano-dispersa con un diametro pico bajo 1000 nm.
CL2007002032A CL2007002032A1 (es) 2006-07-13 2007-07-12 Proceso para elaborar nanodispersiones contra solubles de materiales escasamente solubles en un material vehiculo que comprende proveer una mezcla de una unica fase de una mezcla de solventes miscibles,un material vehiculo soluble en el solvente y un material de carga util soluble en el solvente y secar por aspersion la mezcla por remocion del solvente.
EP07766448A EP2046295A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
ZA200900345A ZA200900345B (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
JP2009518979A JP2009542794A (ja) 2006-07-13 2007-07-13 医薬組成物の調製方法
AU2007274041A AU2007274041A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
EP07766450A EP2046297A2 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
CNA2007800338942A CN101516342A (zh) 2006-07-13 2007-07-13 制备药学组合物的方法
CA002657548A CA2657548A1 (en) 2006-07-13 2007-07-13 Processes for preparing pharmaceutical compositions
CA002657586A CA2657586A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
AU2007274039A AU2007274039A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
CNA2007800338285A CN101516340A (zh) 2006-07-13 2007-07-13 制备药学制剂
US12/309,343 US20100008995A1 (en) 2006-07-13 2007-07-13 Processes for preparing pharmaceutical compositions
BRPI0714351-6A BRPI0714351A2 (pt) 2006-07-13 2007-07-13 processo para produÇço de uma composiÇço opiàide, composiÇço compreendendo opiàide, uso de composiÇço compreendendo opiàide e dispersço compreendendo opiàide
ARP070103116A AR061990A1 (es) 2006-07-13 2007-07-13 Mejoras relacionadas a composiciones antiparasitarias
US12/309,341 US7691873B2 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
JP2009518978A JP2009542793A (ja) 2006-07-13 2007-07-13 製薬組成物の調製
PCT/GB2007/050407 WO2008007150A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
ZA200900347A ZA200900347B (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
ARP070103117A AR061991A1 (es) 2006-07-13 2007-07-13 Mejoras relacionadas a composiciones biocidas
CA002657582A CA2657582A1 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
BRPI0714353-2A BRPI0714353A2 (pt) 2006-07-13 2007-07-13 processos para a preparaÇço de composiÇÕes farmacÊuticas
BRPI0714352-4A BRPI0714352A2 (pt) 2006-07-13 2007-07-13 processo para a produÇço de composiÇço, processo para a preparaÇço de um medicamento, composiÇço obtida pelo referido processo, uso de uma composiÇço, e, dispersço
CNA2007800338444A CN101516341A (zh) 2006-07-13 2007-07-13 制备药学组合物
US12/309,344 US8945626B2 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical compositions
JP2009518980A JP2009542795A (ja) 2006-07-13 2007-07-13 医薬組成物の調製
ARP070103118A AR061992A1 (es) 2006-07-13 2007-07-13 Mejoras referidas a nanodispersiones
EP07766449A EP2046296A2 (en) 2006-07-13 2007-07-13 Processes for preparing pharmaceutical compositions
PCT/GB2007/050409 WO2008007152A2 (en) 2006-07-13 2007-07-13 Preparation of pharmaceutical formulations
PCT/GB2007/050408 WO2008007151A2 (en) 2006-07-13 2007-07-13 Processes for preparing pharmaceutical compositions
AU2007274040A AU2007274040A1 (en) 2006-07-13 2007-07-13 Processes for preparing pharmaceutical compositions
IL195911A IL195911A0 (en) 2006-07-13 2008-12-11 Improvements relating to biocidal compositions
IL195933A IL195933A (en) 2006-07-13 2008-12-15 A process for creating a nano-dispersion antioxidant solution of a soluble substance barely within a carrier material
AU2010201900A AU2010201900A1 (en) 2006-07-13 2010-05-11 Improvements relating to biocidal compositions
CL2010000516A CL2010000516A1 (es) 2006-07-13 2010-05-19 Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).
JP2010131047A JP2010202665A (ja) 2006-07-13 2010-06-08 殺生物性組成物に関連する改良
ARP100102205A AR077195A2 (es) 2006-07-13 2010-06-23 Mejoras relacionadas a composiciones biocidas
US13/365,830 US20120135058A1 (en) 2006-07-13 2012-02-03 Nanodispersions
US13/365,826 US20120134940A1 (en) 2006-07-13 2012-02-03 Nanodispersions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0613925.7A GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions

Publications (1)

Publication Number Publication Date
GB0613925D0 true GB0613925D0 (en) 2006-08-23

Family

ID=36955583

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0613925.7A Ceased GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions

Country Status (17)

Country Link
US (10) US8821932B2 (enExample)
EP (8) EP2040681B1 (enExample)
JP (9) JP2009542764A (enExample)
CN (11) CN102671585A (enExample)
AP (1) AP2008004713A0 (enExample)
AR (4) AR061990A1 (enExample)
AU (9) AU2007271827B2 (enExample)
BR (8) BRPI0714230A2 (enExample)
CA (8) CA2656233A1 (enExample)
CL (4) CL2007002031A1 (enExample)
ES (2) ES2741124T3 (enExample)
GB (1) GB0613925D0 (enExample)
IL (2) IL195911A0 (enExample)
MX (2) MX2009000309A (enExample)
TW (1) TW200812694A (enExample)
WO (8) WO2008006715A2 (enExample)
ZA (7) ZA200900028B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501833D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Carrier liquids and methods of production thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
AR063704A1 (es) * 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
AR067047A1 (es) * 2007-06-18 2009-09-30 Combino Pharm Sl Formulaciones acuosas de acetaminofen para inyeccion.
EP2170313A2 (en) * 2007-06-18 2010-04-07 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
EP2200588B1 (en) 2007-09-25 2019-03-20 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102105136B (zh) * 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
CA2730199C (en) * 2008-07-11 2013-07-30 Nippon Soda Co., Ltd. Method of manufacture of sustained-release formulation composition
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
CN102223790B (zh) 2008-09-25 2015-11-25 维乌作物保护有限公司 生产聚合物纳米颗粒的方法和活性成分的制剂
FR2938433B1 (fr) * 2008-11-19 2011-09-09 Francois Fauran Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
AU2009337187B2 (en) * 2008-12-12 2014-10-23 Azelis New Zealand Limited Compositions for the treatment of timber and other wood substrates
EP2243477A1 (de) * 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
WO2010137888A2 (ko) 2009-05-27 2010-12-02 주식회사 삼양사 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
WO2010151080A2 (ko) * 2009-06-25 2010-12-29 진양제약 주식회사 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
JP5498769B2 (ja) * 2009-12-04 2014-05-21 花王株式会社 脂溶性薬物内包ナノ粒子の製造方法
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
WO2011121515A1 (en) 2010-03-29 2011-10-06 Firmenich Sa Spray-dried crystalline active ingredient
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
UA111167C2 (uk) * 2010-08-05 2016-04-11 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Пестицидні композиції мезорозмірних частинок з підсиленою дією
WO2012045994A1 (en) 2010-10-05 2012-04-12 Iota Nanosolutions Limited Processes for preparing improved compositions
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
WO2012142160A1 (en) 2011-04-12 2012-10-18 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP2013001771A (ja) * 2011-06-14 2013-01-07 Neos Co Ltd 液状カビ防除洗浄剤組成物
RU2469536C1 (ru) * 2011-06-16 2012-12-20 Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" Фунгицидное средство и способ его получения
EA032840B8 (ru) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Пролекарства на основе конъюгатов противогрибковых агентов и их применение
US9686979B2 (en) 2011-08-23 2017-06-27 Vive Crop Protection Inc. Pyrethroid formulations
GB201115079D0 (en) * 2011-08-31 2011-10-19 Iota Nanosolutions Ltd Method of preparing carrier liquids
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
GB201115634D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
US8609684B2 (en) * 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
CA2882679C (en) 2011-12-22 2019-10-15 Vive Crop Protection Inc. Strobilurin formulations
MX374014B (es) * 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
EP3003031A1 (en) 2013-06-04 2016-04-13 Vyome Biosciences Pvt Ltd Coated particles and compositions comprising same
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10287334B2 (en) 2014-03-07 2019-05-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
JP6636952B2 (ja) 2014-06-11 2020-01-29 スペックジーエックス エルエルシー 異なる溶解プロファイルを有する噴霧乾燥組成物及びその調製方法
CN104042626A (zh) * 2014-07-01 2014-09-17 李绍明 杀菌抑菌剂
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
AU2015371232A1 (en) * 2014-12-23 2017-07-27 Dow Global Technologies Llc Treated porous material
JP6730315B2 (ja) * 2015-01-20 2020-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
WO2017004501A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
ES2952606T3 (es) 2015-07-17 2023-11-02 Univ Oklahoma Derivados de licofelona y métodos de uso
CN105145553A (zh) * 2015-10-12 2015-12-16 广西田园生化股份有限公司 一种难溶农药的固体分散体组合物
CN108601342A (zh) * 2016-02-02 2018-09-28 赢创德固赛有限公司 在固体水溶性载体上具有表面活性物质的粉末状配制物、其生产方法和其用途
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
BR112018076184A2 (pt) * 2016-06-16 2019-03-26 The University Of Liverpool composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção.
RU2619249C1 (ru) * 2016-11-07 2017-05-12 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Композиция для протравливания семян и способ её получения
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3601301A1 (en) 2017-03-31 2020-02-05 The University of Liverpool Prodrug compositions
EP3638212B1 (en) * 2017-06-15 2024-05-01 Savior Lifetec Corporation Methods for producing particles of an active ingredient
WO2019038642A1 (en) 2017-08-25 2019-02-28 Vive Crop Protection Inc. MULTI-COMPONENT PESTICIDE COMPOSITIONS APPLIED TO SOIL
US20190269662A1 (en) 2018-03-02 2019-09-05 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
KR20210095132A (ko) 2018-10-04 2021-07-30 럿거스, 더 스테이트 유니버시티 오브 뉴 저지 뉴로메딘 펩티드를 이용하여 2형 사이토카인 매개 염증을 감소시키는 방법
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN109846821B (zh) * 2019-01-03 2021-07-06 昆药集团股份有限公司 一种蒿甲醚纳米制剂及其制备方法
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CN110074993A (zh) * 2019-06-05 2019-08-02 山东大学 一种制备紫外吸收剂纳米颗粒的方法
AU2020302856A1 (en) * 2019-06-28 2022-02-17 Solstar Pharma Extended release gastroretentive formulation against Helicobacter Pylori
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
KR20220090524A (ko) * 2019-10-28 2022-06-29 구미아이 가가쿠 고교 가부시키가이샤 농약조성물 및 그 제조방법
AU2021208631A1 (en) 2020-01-17 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of CRX-autosomal dominant retinopathies
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
IT202000022789A1 (it) 2020-09-28 2020-12-28 Vitop Moulding Srl Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box
GB202115049D0 (en) 2021-10-20 2021-12-01 Univ Liverpool Chemical Compositions
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
GB202304657D0 (en) 2023-03-29 2023-05-10 Univ Liverpool Atovaquine compositions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB501835A (en) 1936-05-29 1939-03-02 Siemens Ag Process and apparatus for reducing the power required for the mechanical treatment of movable masses
GB1305024A (enExample) * 1969-07-10 1973-01-31
GB1554662A (en) * 1976-05-05 1979-10-24 Inverni Della Beffa Spa Polyhydroxyphenylchromanones
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DE3439482A1 (de) 1984-10-27 1986-05-07 Röhm GmbH, 6100 Darmstadt Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US5160530A (en) * 1989-01-24 1992-11-03 Griffin Corporation Microencapsulated polymorphic agriculturally active material
GB8918807D0 (en) * 1989-08-17 1989-09-27 Shell Int Research A solid pesticidal formulation,a process for its preparation and the use thereof
JP3067810B2 (ja) * 1990-12-21 2000-07-24 中外製薬株式会社 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法
GB9304294D0 (en) * 1993-03-03 1993-04-21 Zeneca Ltd Herbicidal compositions
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
TW318777B (enExample) * 1995-06-29 1997-11-01 Novartis Ag
EP0862420A4 (en) 1995-10-13 1999-11-03 Penn State Res Found SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
JP4183279B2 (ja) * 1997-04-15 2008-11-19 アール ピー シェーラー テクノロジーズ インコーポレーテッド 医薬用加水分解セルロース顆粒
CA2322805C (en) * 1998-03-05 2005-09-13 Nippon Shinyaku Co., Ltd. Fat emulsions for inhalational administration
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
GB9904012D0 (en) 1999-02-22 1999-04-14 Zeneca Ltd Agrochemical formulation
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DK1180020T4 (da) 1999-05-27 2009-10-05 Acusphere Inc Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9920148D0 (en) 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
WO2001039836A1 (en) 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
WO2001089484A2 (en) 2000-05-22 2001-11-29 Verion, Inc. Method for increasing the compressibility of poorly binding powder materials
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
AU2002224526A1 (en) * 2000-07-24 2002-02-05 Ono Pharmaceutical Co. Ltd. Freeze-dried preparation of n-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine monosodium salt tetrahydrate and process for producing the same
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
JP2004517699A (ja) * 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
US6355675B1 (en) 2001-05-15 2002-03-12 Isp Investments Inc. Emulsifiable concentrate of a water-insoluble fungicide
ES2348710T5 (es) * 2001-06-01 2014-02-17 Pozen, Inc. Composiciones farmacéuticas para el suministro coordinado de NSAID
ATE480226T1 (de) * 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
EP1420582B1 (en) * 2001-08-21 2012-03-21 Sony Corporation Information processing system; information processing apparatus; and method
IL160570A0 (en) * 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE10151392A1 (de) * 2001-10-18 2003-05-08 Bayer Cropscience Ag Pulverförmige Feststoff-Formulierungen
BR0213905A (pt) * 2001-11-07 2004-08-31 Basf Ag Formulação sólida de proteção de cultura, formulação de dispersão, processo para a preparação das mesmas, copolìmero de radical aleatório, processo para o controle do crescimento indesejável de plantas, e, uso das formulações de proteção de cultura
US20040266626A1 (en) * 2001-11-07 2004-12-30 Wolfgang Schrof Solid crop protection formulations and dispersion formulations and their use in agriculture
JP2005522424A (ja) * 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
JP4865989B2 (ja) * 2002-02-01 2012-02-01 ベンド・リサーチ・インコーポレーテッド 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040028505A1 (en) * 2002-06-07 2004-02-12 Bilbrey Robert A. Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
EP1531799A1 (en) 2002-06-10 2005-05-25 Elan Pharma International Limited Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
AU2003304108B2 (en) * 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
JP2006520746A (ja) * 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
US20060210620A1 (en) 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
US20040197301A1 (en) * 2003-02-18 2004-10-07 Zhong Zhao Hybrid polymers and methods of making the same
US20040162333A1 (en) * 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
AU2004229464A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
US7687167B2 (en) * 2003-07-18 2010-03-30 Panasonic Corporation Power supply unit
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10351004A1 (de) * 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
DE10351087A1 (de) 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
BRPI0418294A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
JP2005298347A (ja) * 2004-04-06 2005-10-27 Yoshiaki Kawashima 吸入製剤及びその製造方法
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
AU2005237213B2 (en) * 2004-04-28 2008-04-24 Unilever Plc Edible oil containing statins
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20060123772A (ko) 2004-06-01 2006-12-04 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 약물의 비결정형의 제조 방법
DE102004031298A1 (de) 2004-06-28 2006-01-12 Basf Ag Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid
KR20070057901A (ko) * 2004-10-01 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 미립자 함유 조성물 및 그의 제조 방법
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP2008526855A (ja) 2005-01-06 2008-07-24 エラン ファーマ インターナショナル リミテッド ナノ粒子のカンデサルタン製剤
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof

Also Published As

Publication number Publication date
AU2007271828A1 (en) 2008-01-17
CN101489532A (zh) 2009-07-22
CA2656229C (en) 2014-05-27
US8945626B2 (en) 2015-02-03
WO2008006712A3 (en) 2009-02-26
US20090239749A1 (en) 2009-09-24
IL195933A0 (en) 2009-09-01
CN102671585A (zh) 2012-09-19
AU2007274040A1 (en) 2008-01-17
WO2008006714A3 (en) 2008-02-21
EP2040681B1 (en) 2017-08-09
AR077195A2 (es) 2011-08-10
ZA200900347B (en) 2010-04-28
AR061992A1 (es) 2008-08-10
ZA200900027B (en) 2010-04-28
EP2040680A2 (en) 2009-04-01
WO2008007151A2 (en) 2008-01-17
ES2741124T3 (es) 2020-02-10
CL2007002030A1 (es) 2008-01-18
EP2386292A1 (en) 2011-11-16
BRPI0722376A2 (pt) 2012-05-22
EP2040679A2 (en) 2009-04-01
US20100068282A1 (en) 2010-03-18
CL2010000516A1 (es) 2010-10-15
JP2009542763A (ja) 2009-12-03
AU2007271829B2 (en) 2011-10-27
EP2040678A2 (en) 2009-04-01
EP2040677A2 (en) 2009-04-01
JP2009542793A (ja) 2009-12-03
WO2008006715A2 (en) 2008-01-17
US20090175953A1 (en) 2009-07-09
CN101516341A (zh) 2009-08-26
WO2008006714A2 (en) 2008-01-17
MX2009000307A (es) 2009-01-26
WO2008006712A2 (en) 2008-01-17
AU2007271830B2 (en) 2010-11-11
US20120135058A1 (en) 2012-05-31
US20090304806A1 (en) 2009-12-10
WO2008007150A1 (en) 2008-01-17
WO2008007152A3 (en) 2008-03-06
US20100015233A1 (en) 2010-01-21
ZA200900028B (en) 2010-04-28
JP2009542760A (ja) 2009-12-03
CN101489535A (zh) 2009-07-22
ZA200900345B (en) 2010-05-26
JP2009542764A (ja) 2009-12-03
WO2008007152A2 (en) 2008-01-17
CA2656229A1 (en) 2008-01-17
WO2008006716A3 (en) 2008-03-13
ZA200900029B (en) 2010-04-28
US8821932B2 (en) 2014-09-02
CN102631874A (zh) 2012-08-15
BRPI0714351A2 (pt) 2013-03-19
EP2040677B1 (en) 2019-05-08
US7691873B2 (en) 2010-04-06
CL2007002031A1 (es) 2008-01-18
BRPI0714179A2 (pt) 2012-12-25
WO2008006716A2 (en) 2008-01-17
JP2009542761A (ja) 2009-12-03
IL195933A (en) 2013-06-27
ZA200900031B (en) 2010-04-28
AU2010201900A1 (en) 2010-06-03
AU2007271830A1 (en) 2008-01-17
WO2008006715A3 (en) 2008-05-08
WO2008007151A3 (en) 2008-03-06
CN101489533A (zh) 2009-07-22
CN101516340A (zh) 2009-08-26
AU2007271831A1 (en) 2008-01-17
CN101516342A (zh) 2009-08-26
CN101489531A (zh) 2009-07-22
EP2040681A2 (en) 2009-04-01
AU2007271829A1 (en) 2008-01-17
US20100008995A1 (en) 2010-01-14
WO2008006713A2 (en) 2008-01-17
CN101489534A (zh) 2009-07-22
ES2752460T3 (es) 2020-04-06
JP2009542762A (ja) 2009-12-03
AU2007271828B2 (en) 2010-12-02
AU2007271831B2 (en) 2010-11-18
CL2007002032A1 (es) 2008-01-18
JP2010202665A (ja) 2010-09-16
MX2009000309A (es) 2009-01-26
BRPI0714177A2 (pt) 2011-05-03
CA2657548A1 (en) 2008-01-17
JP2009542794A (ja) 2009-12-03
JP2009542795A (ja) 2009-12-03
AU2007274041A1 (en) 2008-01-17
CA2656217A1 (en) 2008-01-17
CN101849911A (zh) 2010-10-06
US20100015229A1 (en) 2010-01-21
AR061990A1 (es) 2008-08-10
BRPI0714176A2 (pt) 2012-12-25
EP2040680B1 (en) 2019-08-07
EP2387992A1 (en) 2011-11-23
BRPI0714230A2 (pt) 2013-01-15
AU2007274039A1 (en) 2008-01-17
US9060937B2 (en) 2015-06-23
CA2657586A1 (en) 2008-01-17
BRPI0714353A2 (pt) 2013-05-07
BRPI0714352A2 (pt) 2013-03-19
AU2007271827A1 (en) 2008-01-17
WO2008006713A3 (en) 2008-07-31
CA2656223A1 (en) 2008-01-17
IL195911A0 (en) 2009-09-01
TW200812694A (en) 2008-03-16
AP2008004713A0 (en) 2008-12-31
CA2656233A1 (en) 2008-01-17
AR061991A1 (es) 2008-08-10
AU2007271827B2 (en) 2010-10-14
CA2657582A1 (en) 2008-01-17
CA2659666A1 (en) 2008-01-17
US20090325995A1 (en) 2009-12-31
ZA200900030B (en) 2010-04-28
EP2269581A1 (en) 2011-01-05
US20120134940A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
IL195933A0 (en) Improvements relating to nanodispersions
GB2435863B (en) Folding bicycle
GB2422141B (en) Improvements relating to construction
GB0608386D0 (en) Compounds
GB0616053D0 (en) Improvements relating to hose
GB0605531D0 (en) Improvements Relating To Valves
GB0605786D0 (en) Compounds
GB0609079D0 (en) Improvements relating to hose
GB0612991D0 (en) Improvements relating to hose
ZA201000260B (en) Improvements relating to perfumes
GB0616054D0 (en) Improvements relating to hose
GB0616052D0 (en) Improvements relating to hose
EP2082022A4 (en) COMPOUNDS
GB0606190D0 (en) Construct
GB0614062D0 (en) Compounds
GB0600299D0 (en) Way to go
GB0609081D0 (en) Improvements relating to hose
GB0611654D0 (en) Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
GB0608163D0 (en) Implement
EP1973905A4 (en) COMPOUNDS
GB0625008D0 (en) Improvements relating to kerbs
GB0600637D0 (en) Supplement
GB2423802B (en) Improvements relating to vacuum-brake-boosters
GB0625307D0 (en) Improvements relating to packaging

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)